Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19
Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19 NEW YORK – March 31, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other…